Background. The efficacy of surgery for patients with non-small cell lung cancer is limited, although recent studies suggest that preoperative chemotherapy may improve survival. We conducted a randomized trial to examine the possible benefit of preoperative chemotherapy and surgery for the treatment of patients with non-small cell lung cancer. Methods. We studied 60 patients (59 men and 1 woman) with stage IIIA non-small cell lung cancer. The patients were randomly assigned to receive either surgery alone or three courses of chemotherapy (6 mg of mitomycin per square meter of bodysurface area, 3 g of ifosfamide per square meter, and 50 mg of cisplatin per square meter) given intravenously at three-week intervals and followed bysurgery. Allpatients received mediastinal radiation after surgery. The resected tumors were evaluated by means of K-ras oncogene analysis and flow cytometry. Results. The median period o.f survival was 26 months in the patients treated with chemotherapy plus surgery, as compared with 8 months in the patients treated with surgery alone (P<0.001); the median period of disease-free survival was 20 months in the former group, as compared with 5 months in the latter (P<0.001). The rate of recurrence was 56 percent in the group treated with chemotherapy plus surgery and 74 percent in the group treated with surgery alone. The prevalence of mutated K-ras oncogenes was 15 percent among the patients receiving preoperative chemotherapy and 42 percent among those treated with surgery alone (P=0*05). Most of the patients treated with chemotherapy plus surgery had tumors that consisted of diploid cells, whereas the patients treated with surgery alone had tumors with aneuploid cells. Conclusions. Preoperative chemotherapy increases the median survival in patients with non-small cell lung cancer. (N Engl
perioperative chemotherapy and surgery with those of surgery alone. Methods. This trial was designed to test the null hypothesis that the proportion of patients surviving 3 years is 12% for either treatment group against the alternate hypothesis that the 3-year survival rate would be 12% in the surgery alone group and 32% in the perioperative chemotherapy group. The estimated required sample size was 65 patients in each group. The trial was terminated at an early time according to the method of O'Brien and Fleming following a single unplanned interim analysis. The decision to terminate the trial was based on ethical considerations, the magnitude of the treatment effect, and the high degree of statistical significance attained. In total, 60 patients were randomly assigned between 1987 and 1993 to receive either six cycles of perioperative chemotherapy (cyclophosphamide, etoposide, and cisplatin) and surgery (28 patients) Overall, significant responses were seen in more than 50% of patients and a response usually indicated an improved chance of successful resection. Resection rates ranged from 0% to 88%, with an overall resection rate of more than 50%. The use of preoperative radiotherapy in addition to chemotherapy sometimes made surgery technically more difficult because of post-irradiation fibrosis.2535
The theoretical concern with neoadjuvant chemotherapy is that some patients might progress before surgery. However, the incidence of tumour progression during treatment appears to be quite low; for instance, in one study only seven of 85 patients actually progressed during chemotherapy. 26 Patients in the neoadjuvant arm were treated with three courses of chemotherapy consisting of mitomycin (6 mg/M2), ifosfamide (3mg/m2), and cisplatin (50 mg/m2) as described by Cullen et al.839 All patients received mediastinal radiotherapy following surgery (50 Gy) and were followed up three monthly. The overall response rate in the patients receiving chemotherapy was 60%, with 7% (two patients) achieving a complete response. Only one patient actually had progressive disease during chemotherapy and did not undergo surgery, and two patients refused surgery following chemotherapy. Of the 27 patients operated on in the chemotherapy group, 23 had a complete resection, and in the surgery alone group 27 of the 30 patients had a complete resection. There was no significant difference between the two groups with respect to the surgical procedures that were used or in postoperative complications. There were, however, strikingly significant differences in disease-free and overall survival between the two groups, in both cases favouring the patients who had received preoperative chemotherapy.
The median overall survival in the patients receiving surgery plus radiotherapy alone was eight months compared with 26 months in the group receiving chemotherapy in addition (p<0001). The differences in survival between the groups were significant irrespective of the patient's age or tumour histology, location, size, or the number of N2 nodes involved. Figure 1 shows the survival curves for the two patient groups. What is most striking about this is not the very good survival of the patients treated with chemotherapy before surgery, but the poor survival of the patients who underwent immediate surgery. In this group the median survival was only seven months and there were no patients alive beyond 18 Most series that have reported the effect of radical radiotherapy in patients with stage III disease show a two year survival of 15-20%. 4 Moreover, a recent study of palliative radiotherapy in good performance status patients with non-small cell lung cancer carried out by the MRC has shown a 13% two year survival with high dose palliative radiotherapy. 48 In addition, Rosell and coworkers examined tumour specimens obtained at surgery for the presence of the K-ras oncogene by a technique described by Slebos et al. 49 The presence of K-ras oncogene point mutation has previously been shown to be a significantly adverse prognostic factor in lung cancer.50 52 Such mutations were found in 15% of the patients treated with chemotherapy and in 42% of the control group of patients, and this may account for the very poor survival in the latter group of patients.
As it took 3-4 days to obtain the K-ras oncogene results,49 it was not possible to stratify patients according to the presence or absence of K-ras oncogene point mutations before randomisation. However, technology continues to progress and, indeed, a new and more sensitive assay for K-ras oncogene has recently been described,53 which could mean that this approach may be possible in the future.
In addition, tumour samples from surgery were analysed by flow cytometry to assess the proportion of diploid and aneuploid cells.46 Five of 17 tumour specimens from the chemotherapy plus surgery group (29%) were aneuploid, compared with 14 (70%) of the 20 tumour specimens from the surgery alone group. Radiation therapy has been reported to reduce the aneuploid population in patients with cervical carcinoma,54 so it is possible that the chemotherapy in the neoadjuvant group altered the DNA ploidy of the tumour.
STUDY BY ROTH AND COLLEAGUES3
Sixty patients were entered into this study, all of whom were thought to have resectable stage IlIa disease. Those with clinically obvious N2 disease on CT scanning underwent mediastinoscopy, but those patients with unequivocal plain radiographic evidence of T3 or N2 tumour involvement did not require mediastinoscopy. T3NO patients were classified separately because they are known to have a better prognosis than other patients with stage IIIa disease.
Twenty eight patients were randomised to receive preoperative chemotherapy and figure 2 . The estimated median survival in the chemotherapy group was 64 months compared with 11 months for surgery alone (p<-0 1). In addition, the estimated rates of survival in the chemotherapy group were significantly higher at one, two, and three years than in the surgery alone group (70% versus 45% at one year, 60% versus 25% at two years, and 36% versus 15% at three years).
This study therefore appears to show a significant survival benefit from the addition of neoadjuvant chemotherapy. In fact, as with the study by Rosell 
